Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Residual Disease Detection in Myeloid Malignancies

CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support both DNA and RNA input, the Ion Torrent Oncomine Myeloid MRD Assays (RUO)* provide a comprehensive and highly sensitive MRD assessment from blood and bone marrow samples. Acute myeloid leukemia (AML) is characterized by rapid disease progression and can be fatal if not treated
Click here to view original post